Product name: Saikosaponin A
Synonym name:
Catalogue No.: BP1238
Cas No.: 20736-09-8
Formula: C42H68O13
Mol Weight: 780.993
Botanical Source: Bupleurum falcatum, Bupleurum chinense and Bupleurum kunmingense
Physical Description: Powder
Type of Compound: Triterpenoids
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams, up to kilograms
Inquire for bulk scale.
Descriptions:
Saikosaponin A (SSa), a main constituent of the Chinese herb Bupleurum chinense DC, has antiepileptic activity,could inhibit NMDA receptor current and persistent sodium current, and inhibit epileptiform discharges induced by 4AP in a dose-dependent manner.[1]
Saikosaponin A has anti-inflammatory activity,can decrease PMA plus A23187-induced cysteine-aspartic acid protease (caspase)-1 activity, and the number of nasal rubs and serum TNF-α level in the ovalbumin-sensitized allergic rhinitis mouse model, and inhibit the IL-1β production.[2]
Saikosaponin A extends to alcohol self-administration the capacity to suppress morphine and cocaine self-administration in rats ,the GABA B receptor system is likely part of the neural substrate underlying the reducing effect of SSA on alcohol self-administration. [3]
Saikosaponin A as antioxidants improve antioxidant status. Supplementation with curcumin and/or saikosaponin A suppress inflammation and fibrogenesis in rats with CCl(4)-induced liver injury. However, the combination has no additive effects on anti-inflammation and antifibrosis.[4]
References:
[1] Xie W, Yu Y H, Du Y P, et al. Evid-Based Compl Al, 2013, 2013(1):221-229.
[2] Han N R, Kim H M, Jeong H J.Biol Pharm Bull, 2011, 34(6):817-23.
[3] Maccioni P, Lorrai I, Carai M A M, et al. Neurosci Lett, 2016, 621:62-67.
[4] Shu-JuWu, Ka-WaiTam, Ya-HuiTsai, et al. Am J Chinese Med, 2012, 38(1):99-111.
[5] Tang Y H, Zhang Y Y, Zhu H Y, et al. Biomed Chromatogr, 2007, 21(5):458-62.